

The summary of press release

Colloidal iodine is a new type of formulation for immunotherapy that has a completely different mechanism of action than checkpoint inhibitors. Biogenetical modulation regulates the formation of the gene-cancer protein complex, inhibits activation of cancer genes, and prevents decreased functioning of cancer-inhibiting genes. It allows recovery of immune function homeostasis and shows a marked improvement of response rates and treatment efficacy when used concomitantly with hyperthermotherapy and HBO therapy. Compared to immune checkpoint inhibitors, hardly any adverse drug reactions occur. It is a treatment that has a biochemical modulation (BCM) effect on chemotherapy and, thus, may overcome multidrug resistance to chemotherapy. In a broad sense, colloidal iodine has a biomodulating effect and contributes to improving the effectiveness of cancer treatment.

The cases we presented today were almost all highly advanced cancers in stage 4 or candidates for palliative care. The fact that we were able to achieve rapid and marked improvement of clinical condition in barely a month with no adverse effects allows us to recognize the importance of targeting the TME in cancer for treatment. We believe our findings will have a major impact on the future direction of cancer treatment.